Browse By Person: Pollock, Pamela

Sengal, Asmerom & Pollock, Pamela (2024) Development and Expansion of Patient-Derived Xenografts for Endometrial Cancer. In Saad, Mohamed I. (Ed.) Patient-Derived Xenografts: Methods and Protocols. Humana Press, New York, NY, pp. 101-115.

23

Sengal, Asmerom T., Bonazzi, Vanessa, Smith, Deborah, Moiola, Cristian P., Lourie, Rohan, Rogers, Rebecca, Colas, Eva, Gil-Moreno, Antonio, Frentzas, Sophia, Chetty, Naven, Perrin, Lewis, & Pollock, Pamela M. (2023) Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition. npj Precision Oncology, 7(1), Article number: 127.

21

20

Vermij, Lisa, Leon-Castillo, Alicia, Singh, Naveena, Powell, Melanie E., Edmondson, R., Genestie, Catherine, Khaw, Pearly, Pyman, Jan, McLachlin, C. Meg, Ghatage, Prafull, de Boer, S. M., Nijman, H. W., Smit, V. T.H.B.M., Crosbie, Emma J., Leary, A., Creutzberg, C. L., Horeweg, N., Bosse, T., Kroep, J., Nout, R. A., de Bruyn, M., Kitchener, H. C., Church, D. N., Mileshkin, L., Pollock, P. M., Mackay, Helen J., & other, and (2022) p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial. Modern Pathology, 35(10), pp. 1475-1483.

154

147

Bonazzi, Vanessa F., Kondrashova, Olga, Smith, Deborah, Nones, Katia, Sengal, Asmerom T., Ju, Robert, Packer, Leisl M., Koufariotis, Lambros T., Kazakoff, Stephen H., Davidson, Aimee L., Ramarao-Milne, Priya, Lakis, Vanessa, Newell, Felicity, Rogers, Rebecca, Davies, Claire, Nicklin, James, Garrett, Andrea, Chetty, Naven, Perrin, Lewis, Pearson, John V., Patch, Ann Marie, Waddell, Nicola, & Pollock, Pamela M. (2022) Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. Genome Medicine, 14(1), Article number: 3.

99

28

29

Sengal, Asmerom, Smith, Deborah, Snell, Cameron, Leung, Samuel C. Y., Talhouk, Aline, Williams, Elizabeth, McAlpine, Jessica N., & Pollock, Pamela (2022) Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinoma. Journal of Pathology: Clinical Research, 8(6), pp. 521-537.

192

3

Sengal, Asmerom, Bonazzi, Vanessa, Kondrashova, Olga, Perrin, Lewis, Chetty, Naven, Smith, Deborah, Gil-Moreno, Antonio, Colas, Eva, & Pollock, Pamela (2021) Targeting FGFR2c isoform, a novel therapeutic target with FGFR inhibitor in endometrial cancer. Molecular Cancer Therapeutics, 20(12 Suppl), Article number: Abstract LBA020.

1

Kane, Alexandra M., Liu, Cheng, Fennell, Lochlan J., McKeone, Diane M., Bond, Catherine E., Pollock, Pamela M., Young, Graeme, Leggett, Barbara A., & Whitehall, Vicki L.J. (2021) Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia. British Journal of Cancer, 124(11), pp. 1820-1827.

9

8

Sengal, Asmerom, Smith, Deborah, Rogers, Rebecca, Snell, Cameron, Williams, Elizabeth, & Pollock, Pamela (2021) Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer. Cancers, 13(7), Article number: 1703.

86

8

9

Sengal, Asmerom, Smith, Deborah, Rogers, Rebecca, Snell, Cameron, Williams, Elizabeth, & Pollock, Pamela (2021) FGFR2 isoform switching strongly associates with progestin treatment failure in atypical hyperplasia and well-differentiated endometrial cancer. Clinical Cancer Research, 27(3_Supplement), Article number: Abstract PO033.

McGovern, Jacqui A., Bock, Nathalie, Shafiee, Abbas, Martine, Laure C., Wagner, Ferdinand, Baldwin, Jeremy G., Landgraf, Marietta, Lahr, Christoph A., Meinert, Christoph, Williams, Elizabeth D., Pollock, Pamela M., Denham, Jim, Russell, Pamela J., Risbridger, Gail P., Clements, Judith A., Loessner, Daniela, Holzapfel, Boris M., & Hutmacher, Dietmar W. (2021) A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells. Communications Biology, 4, Article number: 1014.

85

13

12

Landgraf, Marietta, Lahr, Christoph A., Sanchez-Herrero, Alvaro, Meinert, Christoph, Shokoohmand, Ali, Pollock, Pamela M., Hutmacher, Dietmar W., Shafiee, Abbas, & McGovern, Jacqui A. (2020) Correction: Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of Zoledronic acid in vivo. Bone Research, 8, Article number: 17.

124

Leon-Castillo, Alicia, De Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda R., Mackay, Helen J., Leary, Alexandra, Nijman, Hans W., Singh, Naveena, Pollock, Pamela M., Bessette, Paul, Fyles, Anthony, Haie-Meder, Christine, Smit, Vincent T.H.B.M., Edmondson, Richard J., Putter, Hein, Kitchener, Henry C., Crosbie, Emma J., De Bruyn, Marco, Nout, Remi A., Horeweg, Nanda, Creutzberg, Carien L., & Bosse, Tjalling (2020) Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. Journal of Clinical Oncology, 38(29), pp. 3388-3397.

155

734

678

Sengal, Asmerom T., Patch, Ann-Marie, Snell, Cameron E., Smith, Deborah S., Leung, Samuel C.Y., Talhouk, Aline, Williams, Elizabeth D., McAlpine, Jessica N., & Pollock, Pamela M. (2020) FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes. Clinical Cancer Research, 26(17), pp. 4569-4580.

18

17

Bhatia, Sugandha, Blick, Tony, Pinto, Cletus, Waltham, Mark, Monkman, James, Ivanova, Ekaterina, Pollock, Pamela M, Nagaraj, Shivashankar H, Wiegmans, Adrian P, Haviv, Izhak, Simpson, Kaylene J, & Thompson, Erik W (2020) Identifying therapies to combat epithelial mesenchymal plasticity-associated chemoresistance to conventional breast cancer therapies using an shRNA library screen. Cancers, 12(5), Article number: 1123.

178

7

Harrington, Brittney S., He, Yaowu, Khan, Tashbib, Puttick, Simon, Conroy, Paul J., Kryza, Thomas, Cuda, Tahleesa, Sokolowski, Kamil A., Tse, Brian W.C., Robbins, Katherine K., Arachchige, Buddhika J., Stehbens, Samantha J., Pollock, Pamela M., Reed, Sarah, Weroha, S. John, Haluska, Paul, Salomon, Carlos, Lourie, Rohan, Perrin, Lewis C., Law, Ruby H.P., Whisstock, James C., & Hooper, John D. (2020) Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. Theranostics, 10(5), pp. 2095-2114.

82

27

28

Landgraf, Marietta, Lahr, Christoph A., Sanchez-Herrero, Alvaro, Meinert, Christoph, Shokoohmand, Ali, Pollock, Pamela M., Hutmacher, Dietmar W., Shafiee, Abbas, & McGovern, Jacqui A. (2019) Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo. Bone Research, 7, Article number: 31.

117

21

22

Shokoohmand, Ali, Ren, Edward, Baldwin, Jeremy, Atack, Anthony, Shafiee, Abbas, Theodoropoulos, Christina, Wille, Marie-Luise, Tran, Phong, Bray, Laura, Smith, Deborah, Chetty, Naven, Pollock, Pamela, Hutmacher, Dietmar, Clements, Judith, Williams, Elizabeth, & Bock, Nathalie (2019) Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts. Biomaterials, 220, Article number: 119402 1-17.

351

38

36

Packer, Leisl, Stehbens, Samantha, Bonazzi, Vanessa, Gunter, Jennifer, Ju, Robert, Ward, Michael, Gartside, Michael, Byron, Sara, & Pollock, Pamela (2019) Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer. Molecular Oncology, 13(4), pp. 738-756.

173

18

17

Auguste, Aurélie, Genestie, Catherine, De Bruyn, Marco, Adam, Julien, Le Formal, Audrey, Drusch, Françoise, Pautier, Patricia, Crosbie, Emma J., MacKay, Helen, Kitchener, Henry C., Powell, Melanie, Pollock, Pamela M., Mileshkin, Linda, Edmondson, Richard J., Nout, Remi, Nijman, Hans W., Creutzberg, Carien L., Bosse, Tjalling, & Leary, Alexandra (2018) Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. Modern Pathology, 31(12), pp. 1851-1861.

50

39

Packer, Leisl, Byron, Sara, Stehbens, Samantha, Bonazzi, Vanessa, Loch, David, Wortmann, Andreas, Gartside, Mike, Waterhouse, Nigel, Gunter, Jennifer, & Pollock, Pamela M. (2018) FGFR inhibition in endometrial cancer induces caspase-independent cell death that can be augmented with ABT-737. Molecular Cancer Therapeutics, 17(Suppl. 1), Article number: LB-B31.

Stehbens, Samantha, Ju, Robert, Adams, Mark, Perry, Samuel, Haass, Nikolas, Bryant, David, & Pollock, Pamela (2018) FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models. Journal of Cell Science, 131(15), pp. 1-16.

22

23

Karlsson, Thomas, Krakstad, Camilla, Tangen, Ingvild, Hoivik, Erling, Pollock, Pamela, Salvesen, Helga, & Lewis, Aurelia (2017) Endometrial cancer cells exhibit high expression of p110beta and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. OncoTarget, 8(3), pp. 3881-3894.

132

14

Jeske, Yvette, Ali, Shamshad, Byron, Sara, Gao, Feng, Mannel, Robert, Ghebre, Rahel, DiSilvestro, Paul, Lele, Shashikant, Pearl, Michael, Schmidt, Amy, Lankes, Heather, Ramirez, Nilsa, Rasty, Golnar, Powell, Matthew, Goodfellow, Paul, & Pollock, Pamela (2017) FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 145(2), pp. 366-373.

192

50

44

Eggink, Florine, Van Gool, Inge, Leary, Alexandra, Pollock, Pamela, Crosbie, Emma, Mileshkin, Linda, Jordanova, Ekaterina, Adam, Julien, Freeman-Mills, Luke, Church, David, Creutzberg, Carien, De Bruyn, Marco, Nijman, Hans, & Bosse, Tjalling (2017) Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 6(2), Article number: e1264565 1-13.

123

113

Bourke, Lauren, del Monte-Nieto, Gonzalo, Outhwaite, Jennifer, Bharti, Vandha, Pollock, Pamela, Simmons, David, Adam, A., Hur, S., Maghzal, Ghassan, Whitelaw, Emma, Stocker, Roland, Suter, Catherine, Harvey, Richard, & Harten, Sarah (2017) Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouse. Differentiation, 94, pp. 8-20.

11

9

Edmondson, Richard, Crosbie, Emma, Nickkho-Amiry, Mahshid, Kaufmann, Angelika, Stelloo, Ellen, Nijman, Hans, Leary, Alexandra, Auguste, A., Mileshkin, Linda, Pollock, Pamela, Mackay, Helen, Powell, Melanie, Bosse, Tjalling, Creutzberg, Carien, & Kitchener, Henry (2017) Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative. Gynecologic Oncology, 146(3), pp. 327-333.

36

32

Packer, Leisl, Geng, Xinyan, Bonazzi, Vanessa, Ju, Robert, Mahon, Clare, Cummings, Margaret, Stephenson, Sally-Anne, & Pollock, Pamela (2017) PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2-mutant endometrial cancers. Molecular Cancer Therapeutics, 16(4), pp. 637-648.

274

44

Ashton, Nicholas, Paquet, Nicolas, Shirran, Sally, Bolderson, Emma, Kariawasam, Ruvini, Touma, Christine, Fallahbaghery, Azadeh, Gamsjaeger, Roland, Cubeddu, Liza, Botting, Catherine, Pollock, Pamela, O'Byrne, Ken, & Richard, Derek (2017) hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases. DNA Repair, 54, pp. 30-39.

276

13

14

Stark, Mitchell, Tom, Lisa, Boyle, Glen, Bonazzi, Vanessa, Soyer, H. Peter, Herington, Adrian, Pollock, Pamela, & Hayward, Nicholas (2016) The 'Melanoma-enriched' microRNA miR-4731-5p acts as a tumour suppressor. OncoTarget, 7(31), pp. 49677-49687.

124

21

20

Painter, Jodie, Kaufmann, Susanne, O'Mara, Tracy, Hillman, Kristine, Sivakumaran, Haran, Darabi, Hatef, Cheng, Timothy, Pearson, John, Kazakoff, Stephen, Waddell, Nicola, Hoivik, Erling, Goode, Ellen, Scott, Rodney, Tomlinson, Ian, Dunning, Alison, Easton, Douglas, French, Juliet, Salvesen, Helga, Pollock, Pamela, Thompson, Deborah, Spurdle, Amanda, & Edwards, Stacey (2016) A common variant at the 14q32 endometrial cancer risk locus activates AKT1 through YY1 binding. American Journal of Human Genetics, 98(6), pp. 1159-1169.

123

29

26

Painter, Jodie, O'Mara, Tracy, Batra, Jyotsna, Cheng, Timothy, Lose, Felicity, Dennis, Joe, Michailidou, Kyriaki, Tyrer, Jonathan, Ahmed, Shahana, Ferguson, Kaltin, Healey, Catherine, Kaufmann, Susanne, Hillman, Kristine, Walpole, Carina, Moya, Leire, Pollock, Pamela, & other, and (2015) Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 24(5), pp. 1478-1492.

340

48

44

Packer, Leisl & Pollock, Pamela (2015) Paralog-specific kinase inhibition of FGFR4: Adding to the arsenal of anti-FGFR agents. Cancer Discovery, 5(4), pp. 355-357.

324

17

16

Stelloo, Ellen, Bosse, Tjalling, Nout, Remi, Mackay, Helen, Church, David, Nijman, Hans, Leary, Alexandra, Edmondson, Richard, Powell, Melanie, Crosbie, Emma, Kitchener, Henry, Mileshkin, Linda, Pollock, Pamela, Smit, Vincent, & Creutzberg, Carien (2015) Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Modern Pathology, 28(6), pp. 836-844.

447

400

Stark, Mitchell, Bonazzi, Vanessa, Boyle, Glen, Palmer, Jane, Symmons, Judith, Lanagan, Catherine, Schmidt, Chris, Herington, Adrian, Ballotti, Robert, Pollock, Pamela, & Hayward, Nicholas (2015) miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. OncoTarget, 6(19), pp. 17753-17763.

172

88

77

Stark, Mitchell, Klein, Kerenaftali, Weide, Benjamin, Haydu, Lauren, Pflugfelder, Annette, Tang, Yue Hang, Palmer, Jane, Whiteman, David, Scolyer, Richard, Mann, Graham, Thompson, John, Long, Georgina, Barbour, Andrew, Soyer, H. Peter, Garbe, Claus, Herington, Adrian, Pollock, Pamela, & Hayward, Nicholas (2015) The prognostic and predictive value of melanoma-related MicroRNAs using tissue and serum: A MicroRNA expression analysis. EBioMedicine, 2(7), pp. 669-678.

187

96

86

Carroll, Julie-Anne, Janda, Monika, Rodgers, Jessica, Pollock, Pamela M., Choi, Jaz Hee-jeong, & Washington, Tracy L. (2014) ‘Healthy mobile check-ins’ study: Using GIS in smartphones to track use of urban environment by survivors of endometrial cancer. In Australiasian Epidemiological Association Annual Scientific Meeting (AEA 2014), 2014-10-08 - 2014-10-10.

89

Powell, Matthew, Sill, Michael, Goodfellow, Paul, Benbrook, Doris, Lankes, Heather, Leslie, Kimberly, Jeske, Yvette, Mannel, Robert, Spillman, Monique, Lee, Paula, Hoffman, James, McMeekin, Scott, & Pollock, Pamela (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology, 135(1), pp. 38-43.

267

79

69

Getz, Gad, Gabriel, Stacey, Cibulskis, Kristian, Lander, Eric, Sivachenko, Andrey, Sougnez, Carrie, Lawrence, Mike, Kandoth, Cyriac, Dooling, David, Fulton, Robert, Pollock, Pamela, & other, and (2013) Integrated genomic characterization of endometrial carcinoma. Nature, 497(7447), pp. 67-73.

215

4,878

4,625

Byron, Sara, Chen, Huaibin, Wortmann, Andreas, Loch, David, Gartside, Michael, Dehkhoda, Farhad, Blais, Steven, Neubert, Thomas, Mohammadi, Moosa, & Pollock, Pamela (2013) The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia, 15(8), pp. 975-988.

134

120

121

Doudican, Nicole, Byron, Sara, Pollock, Pamela, & Orlow, Seth (2013) XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anti-Cancer Drugs, 24(2), pp. 181-188.

615

53

49

Byron, Sara, Gartside, Michael, Powell, Matthew, Wellens, Candice, Gao, Feng, Mutch, David, Goodfellow, Paul, & Pollock, Pamela (2012) FGFR2 point mutations in 466 endometrioid endometrial tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One, 7(2), pp. 1-9.

469

167

148

Byron, Sara, Loch, David, & Pollock, Pamela (2012) Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. International Journal of Gynecological Cancer, 22(9), pp. 1517-1526.

375

32

28

Loch, David & Pollock, Pamela (2012) Lineage-specific biomarkers predict response to FGFR inhibition. Cancer Discovery, 2(12), pp. 1081-1083.

228

1

Byron, Sara, Loch, David, Wellens, Candice, Wortmann, Andreas, Wu, Jiayi, Wang, John, Nomoto, Kenichi, & Pollock, Pamela (2012) Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Molecular Cancer, 11(October), pp. 1-27.

651

37

34

Wortmann, Andreas, He, Yaowu, Christensen, Melinda, Linn, May, Lumley, John, Pollock, Pamela, Waterhouse, Nigel, & Hooper, John (2011) Cellular settings mediating Src substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. Journal of Biological Chemistry, 286(49), pp. 42303-42315.

252

31

30

Greulich, Heidi & Pollock, Pamela (2011) Targeting mutant fibroblast growth factor receptors in cancer. Trends in Molecular Medicine, 17(5), pp. 283-292.

636

116

111

Byron, Sara, Gartside, Michael, Wellens, Candice, Goodfellow, Paul, Birrer, Michael, Campbell, Ian, & Pollock, Pamela (2010) FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecologic Oncology, 117(1), pp. 125-129.

392

36

Terzian, Tamara, Torchia, Enrique C., Dai, Daisy, Robinson, Steven E., Murao, Kazutoshi, Stiegmann, Regan A., Gonzalez, Victoria, Boyle, Glen M., Powell, Marianne B., Pollock, Pamela M., Lozano, Guillermina, Robinson, William A., Roop, Dennis R., & Box, Neil F. (2010) p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell and Melanoma Research, 23(6), pp. 781-794.

58

55

Pinnix, Chelsea, Lee, John, Liu, Zhao-Jun, McDaid, Ronan, Balint, Klara, Beverly, Levi, Brafford, Patricia, Xiao, Min, Himes, Benjamin, Zabierowski, Susan, & Pollock, Pamela (2009) Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Research, 69(13), pp. 5312-5320.

169

106

103

Byron, Sara & Pollock, Pamela (2009) FGFR2 as a molecular target in endometrial cancer. Future Oncology, 5(1), pp. 27-32.

51

47

Kalinina, Juliya, Byron, Sara, Makarenkova, Helen, Olsen, Shaun, Eliseenkova, Anna, Larochelle, William, Dhanabal, Mohanraj, Blais, Steven, Ornitz, David, Day, Loren, Neubert, Thomas, Pollock, Pamela, & Mohammadi, Moosa (2009) Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Molecular and Cellular Biology, 29(17), pp. 4663-4678.

44

40

Gartside, Michael, Chen, Huaibin, Ibrahimi, Omar, Byron, Sara, Curtis, Amy, Wellens, Candice, Bengston, Ana, Yudt, Laura, Eliseenkova, Anna, Ma, Jinghong, & Pollock, Pamela (2009) Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Molecular Cancer Research, 7(1), pp. 41-54.

596

113

110

Byron, S. A., Gartside, M. G., Wellens, C. L., Mallon, M. A., Keenan, J. B., Goodfellow, P. J., Powell, M. A., & Pollock, P. M. (2008) Correction: Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation (Cancer Research (September 1, 2008) 68 (6902-6907)). Cancer Research, 68(23), p. 10005.

1

Huynh, Hung, Ngo, Van Chanh, Fargnoli, Joseph, Ayers, Mark, Soo, Khee Chee, Nung, Koong Heng, Thng, Choon Hua, Ong, Hock Soo, Chung, Alexander, Chow, Pierce, Pollock, Pamela, Byron, Sara, & Tran, Evelyn (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clinical Cancer Research, 14(19), pp. 6146-6153.

216

202

Zhao, Zhen Zhen, Pollock, Pamela, Thomas, Shane, Treloar, Sue, Nyholt, Dale, & Montgomery, Grant (2008) Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk. Human Reproduction, 23(7), pp. 1661-1668.

10

9

Byron, Sara, Gartside, Michael, Wellens, Candice, Mallon, Mary, Keenan, Jack, Powell, Matthew, Goodfellow, Paul, & Pollock, Pamela (2008) Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Research, 68(17), pp. 6902-6907.

500

131

125

Chen, Huaibin, Xu, Chong-Feng, Ma, Jinghong, Eliseenkova, Anna, Li, Wanqing, Pollock, Pamela, Pitteloud, Nelly, Miller, W. Todd, Neubert, Thomas, & Mohammadi, Moosa (2008) A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proceedings of the National Academy of Sciences of the United States of America, 105(50), pp. 19660-19665.

60

56

Pollock, Pamela, Gartside, Michael, Dejeza, L., Powell, Matthew, Mallon, M., Davies, H., Mohammadi, Moosa, Futreal, P., Stratton, Michael, Trent, Jeffrey, & Goodfellow, Paul (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene, 26(50), pp. 7158-7162.

272

252

Packer, Leisl, Pavey, Sandra, Parker, Andrew, Stark, Mitchell, Johansson, Peter, Clarke, Belinda, Pollock, Pamela, Ringner, Markus, & Hayward, Nicholas (2006) Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis, 27(9), pp. 1778-1786.

53

49

Nickoloff, Brian, Hendrix, Mary, Pollock, Pamela, Trent, Jeffrey, Miele, Lucio, & Qin, Jian-Zhong (2005) Notch and NOXA-related pathways in melanoma cells. The Journal of Investigative Dermatology Symposium Proceedings, 10(2), pp. 95-104.

64

54

Qin, Jian-Zhong, Ziffra, Jeffrey, Stennett, Lawrence, Bodner, Barbara, Bonish, Brian, Chaturvedi, Vijaya, Bennett, Frank, Pollock, Pamela, Trent, Jeffrey, Hendrix, Mary, Rizzo, Paola, Miele, Lucio, & Nickoloff, Brian (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Research, 65(14), pp. 6282-6293.

295

281

Walker, Graeme, Indsto, James, Sood, Raman, Faruque, Mezbah, Hu, Ping, Pollock, Pamela, Duray, Paul, Holland, Elizabeth, Brown, Kevin, Kefford, Richard, Trent, Jeffrey, Mann, Graham, & Hayward, Nicholas (2004) Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-mb interval. Genes Chromosomes and Cancer, 41(1), pp. 56-64.

30

29

Pavey, Sandra, Johansson, Peter, Packer, Leisl, Taylor, Jennifer, Stark, Mitchell, Pollock, Pamela, Walker, Graeme, Boyle, Glen, Harper, Ursula, & Cozzi, Sarah-Jane (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene, 23(23), pp. 4060-4067.

157

145

Qin, Jian-Zhong, Stennett, Lawrence, Bacon, Patricia, Bodner, Barbara, Hendrix, Mary, Seftor, Richard, Seftor, Elisabeth, Margaryan, Naira, Pollock, Pamela, Curtis, Amy, Trent, Jeffrey, Bennett, Frank, Miele, Lucio, & Nickoloff, Brian (2004) p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Molecular Cancer Therapeutics, 3(8), pp. 895-902.

120

117

Pollock, P.M., Harper, U.L., Hansen, K.S., Yudt, L.M., Stark, M., Robbins, C.M., Moses, T.Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N.K., Trent, J.M., & Meltzer, P.S. (2003) High frequency of BRAF mutations in nevi. Nature Genetics, 33(1), pp. 19-20.

1,491

1,332

Pollock, Pamela, Cohen-Solal, Karine, Sood, Raman, Namkoong, Jin, Martino, Jeffrey, Koganti, Aruna, Zhu, Hua, Robbins, Christiane, Makalowska, Izabela, & Shin, Seung-Shick (2003) Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nature Genetics, 34(1), pp. 108-112.

263

252

Pollock, Pamela M. & Meltzer, Paul S. (2002) Lucky draw in the gene raffle. Nature, 417(6892), pp. 906-907.

21

19

Pollock, Pamela M. & Hayward, Nicholas K. (2002) Mutations in exon 3 of the beta-catenin gene are rare in melanoma cell lines. Melanoma Research, 12(2), pp. 183-186.

33

30

Pollock, P.M., Walker, G.J., Glendening, J.M., Que Noy, T., Bloch, N.C., Fountain, J.W., & Hayward, N.K. (2002) PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Research, 12(6), pp. 565-575.

58

48

Pollock, Pamela M. & Meltzer, Paul S. (2002) A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell, 2(1), pp. 5-7.

146

123

Pollock, Pamela M., Stark, Mitchell, Palmer, Jane M., Walters, Marilyn K., Martin, Nick G., Green, Adele C., & Hayward, Nicholas K. (2001) Mutation analysis of the cdkn2a promoter in australian melanoma families. Nature Genetics, 27(4S), p. 80.

Cook, Anthony L., Pollock, Pamela M., Welch, John, Walsh, Michael D., Bowman, Rayleen V., Baumann, Kathryn C., Hayward, Nicholas K., & Leonard, J. Helen (2001) CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. International Journal of Cancer, 93(3), pp. 361-367.

12

Pollock, Pamela M., Welch, John, & Hayward, Nicholas K. (2001) Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Research, 61, pp. 1154-1161.

68

64

Pollock, Pamela M., Stark, Mitchell S., Palmer, Jane M., Walters, Marilyn K., Aitken, Joanne F., Martin, N. G., & Hayward, Nicholas K. (2001) Mutation analysis of the CDKN2A promoter in Australian melanoma families. Genes, Chromosomes and Cancer, 32(1), pp. 89-94.

20

18

Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., Sampas, N., Dougherty, E., Wang, E., Marincola, F., Gooden, C., Lueders, J., Glatfelter, A., Pollock, P.M., Carpten, J., Gillanders, E., Leja, D., Dietrich, K., Beaudry, C., Berens, M., Alberts, D., & Sondak, V. (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 406(6795), pp. 536-540.

1,793

1,580

Pollock, P.M. & Trent, J.M. (2000) The genetics of cutaneous melanoma. Clinics in Laboratory Medicine, 20(4), pp. 667-690.

56

45

Pollock, Pamela M., Spurr, Nigel, Bishop, Tim, Newton-Bishop, Julia, Gruis, Nelleke, van der Velden, Pieter A., Goldstein, Alisa M., Tucker, Margaret A., Foulkes, William D., Barnhill, Ray, Haber, Daniel, Fountain, Jane W., & Hayward, Nicholas K. (1998) Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families : evidence for common founders and independent mutations. Human Mutation, 11(6), pp. 424-431.

58

53

Flores, Jose F., Pollock, Pamela M., Walker, Graeme J., Glendening, J. Michael, Lin, Amy H-T, Palmer, Jane M., Walters, Marilyn K., Hayward, Nicholas K., & Fountain, Jane W. (1997) Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene, 15(24), pp. 2999-3005.

73

67

Foulkes, William D., Flanders, Tamar Y., Pollock, Pamela M., & Hayward, Nicholas K. (1997) The CDKN2A (p16) gene and human cancer. Molecular Medicine, 3(1), pp. 5-20.

257

250

Sun, Sophie, Pollock, Pamela M., Liu, Ling, Karimi, Sepideh, Jothy, Serge, Milner, Benedict J., Renwick, Andrew, Lassam, Norman J., Hayward, Nicholas K., Hogg, David, Narod, Steven A., & Foulkes, William D. (1997) CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. International Journal of Cancer, 73(4), pp. 531-536.

54

45

Castellano, Marina, Pollock, Pamela M., Walters, Marilyn K., Sparrow, Louise E., Down, Louise M., Gabrielli, Brian G., Parsons, Peter G., & Hayward, Nicholas K. (1997) CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Research, 57(21), pp. 4868-4875.

138

135

Grimmond, S., Lagercrantz, J., Drinkwater, C., Silins, G., Townson, S., Pollock, P.M., Gotley, D., Carson, E., Rakar, S., Nordenskjold, M., Ward, L., Hayward, N., & Weber, G. (1996) Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Research, 6(2), pp. 124-131.

122

120

Pollock, Pamela M., Pearson, John V., & Hayward, Nicholas K. (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers : non-random distribution of base substitutions. Genes Chromosomes and Cancer, 15(2), pp. 77-88.

169

173

Pollock, P.M., Yu, F., Qiu, L., Parsons, P.G., & Hayward, N.K. (1995) Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene, 11(4), pp. 663-668.

115

109

Yulug, Isik G., Egan, Sean E., Pollock, Pamela M., & Fisher, Elizabeth M.C. (1993) A homologue of the Drosophila Son of sevenless gene maps to mouse chromosome 17. Genomics, 18(3), pp. 733-734.

5

6

Export as	Atom RSS 1.0 RSS 2.0